Myelin peptide–major histocompatibility complex

Myelin peptide–major histocompatibility complex refers to immunological complexes formed when myelin-derived peptides (such as fragments of myelin basic protein) are bound by major histocompatibility complex (MHC) molecules, typically of class II, on antigen-presenting cells. These complexes are crucial in both healthy immune surveillance and the pathogenesis of autoimmune diseases such as multiple sclerosis, where they are recognized by autoreactive T-cell receptors, leading to demyelination and CNS inflammation[2][4][5]. The structural properties of the MHC peptide-binding groove and the sequence of the myelin peptide determine the specificity and strength of T-cell recognition[1][2][3]. There is extensive polymorphism in MHC molecules, influencing which myelin peptides are presented and hence the likelihood of autoimmunity in genetically susceptible individuals[1][4]. The activation of autoreactive CD4+ T cells by these complexes is a key event in the development of CNS autoimmunity, but the complex as such is not a classical drug target[5]. In summary, "myelin peptide–major histocompatibility complex" is a descriptive immunological entity rather than a distinct, actionable molecular target; entries should be constructed for specific MHC molecules (e.g., HLA-DRB1*15:01) and individual myelin peptides (e.g., MBP 85-99), not their generic complex.

Other names

MBP–MHC complexmyelin peptide–MHC complexpeptide–MHC complex (very generic)myelin antigen–MHC complex